STOK
NASDAQStoke Therapeutics Inc.
Price$24.20+0.09 (+0.37%)
01:30 PM07:45 PM
News · 26 weeks65+120%
2026-04-192026-10-11
Mix3290d
- Other13(41%)
- Insider9(28%)
- SEC Filings6(19%)
- Earnings2(6%)
- Analyst1(3%)
- Leadership1(3%)
Latest news
25 items- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Company’s newly-appointed Senior Vice President, Chief Information Officer, and seventeen other new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The company granted Mr. Asch
- PRStoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision loss– –STK-002 represents a novel approach to ADOA by targeting the underlying disease biology, with the potential to be the first disease-modifying medicine for people living with ADOA– –ADOA natural history findings and preclinical proof-of-concept data for STK-002 support the ongoing Phase 1 OSPREY study in people with ADOA– –Dosing is now complete in first two cohorts of OSPREY study, with dosing of third cohort expected to complete by the end of 2026; initial safety and effic
- PRStoke Therapeutics Announces Presentations of STK-002, an Investigational Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA), at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting–ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in insufficient levels of OPA1 protein, leading to progressive and irreversible vision loss– –Preclinical data and progress of the Phase 1 OSPREY study of STK-002 in people with ADOA will be presented at AAO 2026– –Dosing is now complete in first two cohorts of OSPREY study, with dosing of third cohort expected to complete by year-end 2026; initial safety and efficacy data anticipated in H1 2027– Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today annou
- PRStoke Therapeutics Announces Completion of Successful Meeting with the FDA to Align on Planned U.S. NDA for Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome– Analysis of the Phase 3 EMPEROR key secondary endpoint of changes in cognition and behavior will be performed using a multicomponent assessment of four Vineland-3 subdomains – – Phase 3 readout anticipated in the third quarter of 2027 to complete the planned U.S. NDA submission in the second half of 2027 – Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced the completion of a successful meeting with the
- INSIDERGENERAL COUNSEL & CORP SEC Allan Jonathan sold $16,509 worth of shares (627 units at $26.33) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 20,598 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $27,494 worth of shares (1,051 units at $26.16) as part of a pre-agreed trading plan, decreasing direct ownership by 5% to 19,059 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Stoke Therapeutics Inc.SCHEDULE 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
- INSIDERSEC Form 4 filed by Stoke Therapeutics Inc.4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cumbo Alexander3 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- SECSEC Form 8-K filed by Stoke Therapeutics Inc.8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
- PRStoke Therapeutics Appoints Bo Cumbo to its Board of Directors, Enhancing Commercial Expertise as the Company Advances Zorevunersen Development Toward Potential FDA Approval and Commercialization–Mr. Cumbo brings deep experience commercializing new medicines for people with rare genetic diseases– –Company announces retirement of Director Edward Kaye, M.D., from the Board– Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Bo Cumbo to its Board of Directors. Concurrent with Mr. Cumbo’s appointment, Edward Kaye, M.D., has retired from his role as a Director on Stoke’s Board. Dr.
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on September 15, 2026, it granted stock options to purchase an aggregate of 53,175 shares of common stock to nine new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $28.15 per share, which is equal to the closing price of
- PRStoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)–4-year data from the Phase 1/2a open-label extension (OLE) studies showed substantial and durable reductions in seizures and continuing improvements in cognition and behavior in patients treated with zorevunersen on top of standard of care anti-seizure medicines– –New data showed substantial reductions in the most severe seizure types, the leading risk factor for sudden unexpected death in epilepsy (SUDEP)– –Improvements in quality of life were demonstrated through 28 months of treatment– –Zorevunersen generally well tolerated, with some patients treated for more than 5 years– –Data from the global, pivotal Phase 3 EMPEROR study anticipated in Q3 2027 to complete the planned rolling U.S
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $170,061 worth of shares (5,545 units at $30.67) as part of a pre-agreed trading plan, decreasing direct ownership by 22% to 20,110 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics to Present at the Cantor Global Healthcare ConferenceStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 1:00 p.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website at https://investor.stoketherapeutics
- PRStoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, in addition to durable seizure reductions and a generally well-tolerated safety profile– –New data from sub-analyses of patients treated with zorevunersen in the Phase 1/2a OLEs include effects on severe seizures and quality of life– BEDFORD, Mass. and CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (NASDAQ:BIIB
- ANALYSTAnalyst resumed coverage on Stoke Therapeutics with a new price targetAnalyst resumed coverage of Stoke Therapeutics with a rating of Overweight and set a new price target of $40.00
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry converted options into 10,000 shares and sold $152,690 worth of shares (4,767 units at $32.03), increasing direct ownership by 26% to 25,655 units (SEC Form 4) to satisfy withholding tax4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERDirector Kaye Edward M. Md converted options into 26,250 shares and sold $402,528 worth of shares (12,567 units at $32.03), increasing direct ownership by 12% to 124,557 units (SEC Form 4) to satisfy withholding obligation4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- INSIDERGENERAL COUNSEL & CORP SEC Allan Jonathan converted options into 6,000 shares and sold $91,639 worth of shares (2,861 units at $32.03), increasing direct ownership by 17% to 21,225 units (SEC Form 4) (tax withholding)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on August 17, 2026, it granted stock options to purchase an aggregate of 70,950 shares of common stock to seven new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $32.13 per share, which is equal to the closing price of S
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
- INSIDERCHIEF MEDICAL OFFICER Ticho Barry sold $208,385 worth of shares (7,176 units at $29.04) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 20,422 units (SEC Form 4)4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
- PRStoke Therapeutics to Present at the Canaccord Genuity 46th Annual Growth ConferenceStoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith and Chief Patient Officer Jason Hoitt will present at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at 11:00 a.m. ET. A live webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke’s website at https://investor.stoket
STOK FAQ
7 questionsWhat does Stoke Therapeutics Inc. do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera...Where does STOK stock trade?
Stoke Therapeutics Inc. (STOK) is listed on NASDAQ.What sector and industry is STOK in?
Stoke Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Stoke Therapeutics Inc. go public?
Stoke Therapeutics Inc. (STOK) completed its IPO in 2019.What are analysts saying about STOK?
Stoke Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Analyst: Overweight with a $4000.00 price target on 2026-08-21. Recent price targets range from $1800.00 to $4400.00.What companies are similar to STOK?
Notable peers in the same industry include GTHX (G1 Therapeutics Inc.), GRTX (Galera Therapeutics Inc.), MCRB (Seres Therapeutics Inc.). Compare STOK side-by-side with any of them on Quantisnow.How can I track STOK on Quantisnow?
Quantisnow aggregates Stoke Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STOK to receive live email and push alerts on every new disclosure.